Cargando…

OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form

Detalles Bibliográficos
Autores principales:	Fudin, Jeffrey, Raouf, Mena, Wegrzyn, Erica L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019471/ https://www.ncbi.nlm.nih.gov/pubmed/27660487 http://dx.doi.org/10.2147/JPR.S117219

Ejemplares similares

Pharmacokinetics, Tolerability, and Safety of Intranasal Administration of Reformulated OxyContin(®) Tablets Compared with Original OxyContin(®) Tablets in Healthy Adults
por: Perrino, Peter J., et al.
Publicado: (2013)

The controversy surrounding OxyContin abuse: issues and solutions
por: Jayawant, Sujata S, et al.
Publicado: (2005)

OxyContin and the McDonaldization of chronic pain therapy in the USA
por: Hughes, Jordan, et al.
Publicado: (2019)

On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data
por: Pappin, Jessie, et al.
Publicado: (2022)

An Evaluation of the Effect of the OxyContin Reformulation on Unintentional Fatal and Nonfatal Overdose
por: Beachler, Daniel C., et al.
Publicado: (2022)

Monitoring of Internet Forums to Evaluate Reactions to the Introduction of Reformulated OxyContin to Deter Abuse
por: McNaughton, Emily C, et al.
Publicado: (2014)

Perceptions of Community-Dwelling Patients and Their Physicians on OxyContin® Discontinuation and the Impact on Chronic Pain Management
por: Chang, Feng, et al.
Publicado: (2017)

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†
por: Sessler, Nelson E, et al.
Publicado: (2014)

The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting
por: Coplan, PM, et al.
Publicado: (2016)

High-dose OxyContin to treat pain associated with bone metastasis in patients with small-cell lung cancer: a case study report
por: Zhou, Tao, et al.
Publicado: (2016)

Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties
por: Janoff, Shannon L., et al.
Publicado: (2016)

Safety concerns with the Centers for Disease Control opioid calculator
por: Fudin, Jeffrey, et al.
Publicado: (2017)

Standardized nursing and clinical efficacy of OxyContin in reducing oral mucosal pain in patients with nasopharyngeal carcinoma: A randomized, double-blind, placebo-controlled study protocol
por: Sun, Nina, et al.
Publicado: (2020)

A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin
por: Olatoke, Oluwadara, et al.
Publicado: (2022)

Contracts Submitted for Post Hoc Approval by Finance Committee
Publicado: (1959)

Getting approval for new therapeutic medical devices versus drugs: are the differences justified?
por: Frigerio, Maria
Publicado: (2016)

Rational dosing of gabapentin and pregabalin in chronic kidney disease
por: Raouf, Mena, et al.
Publicado: (2017)

Can we not work together to help family practitioners become more effective pain managers?
por: Fudin, Jeffrey, et al.
Publicado: (2016)

The research on long-term clinical effects and patients’ satisfaction of gabapentin combined with oxycontin in treatment of severe cancer pain
por: Chen, Dong-Liang, et al.
Publicado: (2016)

Comparing cost and effectiveness of IVPCA morphine with perioperative multimodal analgesia of oral etoricoxib and oxycontin: A retrospective study()
por: Chen, Pik Yu, et al.
Publicado: (2019)

The European Medicines Agency's approval of new medicines for type 2 diabetes
por: Blind, Eberhard, et al.
Publicado: (2018)

Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World
por: Fernández-Garza, Luis E., et al.
Publicado: (2023)

Pharmacotherapeutic considerations for chronic pain in chronic kidney and end-stage renal disease
por: Mathew, Roy O, et al.
Publicado: (2016)

Pharmacogenetic guidance: individualized medicine promotes enhanced pain outcomes
por: Dragic, Lisa Lynn, et al.
Publicado: (2017)

Fentalogues
por: Persico, Amelia L, et al.
Publicado: (2020)

Green adherent spectrophotometric determination of molnupiravir based on computational calculations; application to a recently FDA-approved pharmaceutical dosage form
por: Abdelazim, Ahmed H., et al.
Publicado: (2023)

Pharmaceutical dosage forms : parenteral medications /
Publicado: (1992)

Pharmaceutical dosage forms : disperse systems
Publicado: (1996)

Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer
por: Alsina, Maria, et al.
Publicado: (2019)

Is Gastrostomy Justifiable?
Publicado: (1909)

Introduction to pharmaceutical dosage forms /
por: Ansel, Howard C., 1933-
Publicado: (1976)

Pharmaceutical dosage forms--tablets /
Publicado: (1989)

Justified defection is neither justified nor unjustified in indirect reciprocity
por: Yamamoto, Hitoshi, et al.
Publicado: (2020)

Best Practices for the Development, Scale-up, and Post-approval Change Control of IR and MR Dosage Forms in the Current Quality-by-Design Paradigm
por: Van Buskirk, Glenn A., et al.
Publicado: (2014)

Eco-friendly simultaneous multi-spectrophotometric estimation of the newly approved drug combination of celecoxib and tramadol hydrochloride tablets in its dosage form
por: Ramadan, Hesham Sameh, et al.
Publicado: (2023)

A Randomized, Crossover, Pharmacokinetic and Adhesion Performance Study of a Lidocaine Topical System 1.8% During Physical Activity and Heat Treatment in Healthy Subjects
por: Fudin, Jeffrey, et al.
Publicado: (2020)

Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies
por: Spelsberg, Angela, et al.
Publicado: (2017)

Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency
por: Orellana García, Laura Patricia, et al.
Publicado: (2021)

Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014
por: Cherla, Avi, et al.
Publicado: (2022)

Opioid Taper Practices Among Clinicians
por: Persico, Amelia L, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_beml55sbhm82hob8esbf8g562c